Quantcast
Home > Quotes > UMRX

Unum Therapeutics Inc. Common Stock (UMRX) Quote & Summary Data

UMRX 
$1.71
*  
0.28
14.07%
Get UMRX Alerts
*Delayed - data as of Aug. 23, 2019  -  Find a broker to begin trading UMRX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
10.5
Today's High / Low
$ 2.08 / $ 1.71
Share Volume
27,090
50 Day Avg. Daily Volume
219,471
Previous Close
$ 1.99
52 Week High / Low
$ 16.72 / $ 1.50
Market Cap
52,429,547
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -1.36
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.41

Intraday Chart

Shares Traded

Share Volume:
27,090
50 Day Avg. Daily Volume:
219,471

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.36

Trading Range

The current last sale of $1.71 is 14.00% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.08 $ 16.72
 Low: $ 1.71 $ 1.50

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Our proprietary technologies include a universal, engineered cell therapy, referred to as Antibody-Coupled T cell Receptor (ACTR), that is intended to be used in combination with a wide range of tumor-specific antibodies to target different tumor types. In addition, we have developed a second novel technology, Bolt-On Chimeric Receptor (BOXR), for improving T cell functionality in solid tumor cancer applications by overcoming immunosuppressive tumor microenvironments. BOXR T cells may be directed to attack tumor cells using a variety of targeting strategies and our efforts to date have demonstrated activity using either ACTR or scFv-based CAR receptors.  ... More ...  



Risk Grade

Where does UMRX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.98
Open Date:
Aug. 23, 2019
Close Price:
$ 1.71
Close Date:
Aug. 23, 2019


Consensus Recommendation

Analyst Info